Curanex Pharmaceuticals Inc. CURX 深 滬
等待開盤 06-25 09:30:00 美东时间
0.265
-0.009
-3.28%
華盛通- 最 高0.2778
- 今 開0.2704
- 成交量 4.59万股
- 最 低 0.265
- 昨 收 0.274
- 總市值 751.67万
- 52周最高 9.1796
- 市盈率 靜 --
- 換手率 0.16%
- 52周最低 0.262
- 委 比 97.30%
- 總股本 2836.48万
- 歷史最高 9.1796
- 量 比 0.47
- 振 幅 4.67%
- 歷史最低 0.262
- 每 手 1
- 風險率 1.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Curanex Advances Phyto-N Program and Expands Indications
An announcement from Curanex Pharmaceuticals Inc. ( ($CURX) ) is now available....
05-14 21:54
Curanex Pharmaceuticals Q1 EPS $(0.11) Down From $(0.01) YoY
Curanex Pharmaceuticals (NASDAQ:CURX) reported quarterly losses of $(0.11) per share. This is a 1000 percent decrease over losses of $(0.01) per share from the same period last year.
05-14 21:05
Curanex Continues To Advance Phyto-N As Lead Development Candidate, With Ulcerative Colitis As Initial Target Indication; Co. Prepares Phyto-N For Planned IND Submission In Q4 Of 2026
Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitisExpanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition
05-14 20:56
Curanex Q1 FY26 net loss widens to $3.15 million
Curanex Q1 FY26 net loss widens to $3.15 million Curanex posted a net loss of USD 3.15 million for Q1 ended March 31, 2026, widening from a loss of USD 137,583 a year earlier, while reporting no revenue. General and administrative expense climbed to USD 927,197 from USD 137,452, driven by higher per
05-14 20:48
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Immutep (NASDAQ:IMMP) shares rose 135.4% to $0.74 during Wednesday's p...
04-15 20:05
EXCLUSIVE: Penny Stock Curanex Expands Cachexia Focus Backed By Patient Recovery Narratives
Curanex highlights patient cases suggesting its lead candidate may aid cachexia and severe disease recovery.
04-08 19:33
EXCLUSIVE: Curanex Pipeline Expansion Signals Push Beyond Inflammation, Metabolic Diseases
Curanex expands pipeline with cancer cachexia, advances Phyto-N toward IND, and reports preclinical safety data.
04-02 19:53
Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission
Curanex Pharmaceuticals在制造、毒理学、专利和监管方面取得进展，推动其主要资产Phyto-N溃疡性结肠炎治疗IND申请。公司完成了GLP毒理学研究，扩大知识产权，并评估其他治疗领域。计划于2026年第四季度提交IND，并在澳大利亚启动I期临床，预计溃疡性结肠炎市场到2030年达113.9亿美元。
03-30 21:35
Curanex Phyto-N repeat-dose study shows no toxicology findings at maximum feasible dose
Curanex Phyto-N repeat-dose study shows no toxicology findings at maximum feasible dose Curanex reported results from a 28-day repeat-dose, dose-range finding toxicology study of its botanical drug candidate Phyto-N in Sprague-Dawley rats and dogs. Phyto-N was administered orally twice daily, and no
03-19 08:43
Curanex appoints Taku Kambayashi and Selvakumar Subbian to scientific advisory board
Curanex appoints Taku Kambayashi and Selvakumar Subbian to scientific advisory board Curanex appointed Taku Kambayashi and Selvakumar Subbian to its Scientific Advisory Board. Taku Kambayashi is a Professor of Pathology and Laboratory Medicine at the University of Pennsylvania’s Perelman School of M
03-12 21:30
